# Sera Prognostics, Inc.: financial statements, quarterly

SERA · Nasdaq · CIK 1534969 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sera.md) · [Financials](/companies/sera/financials.md) · [Filings](/companies/sera/filings.md) · [Insiders](/companies/sera/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sera/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-122312.md) | [0.0 d](/filings/0000950170-25-042017.md) | [0.0](/filings/0000950170-25-065667.md) | [0.0](/filings/0000950170-25-104007.md) | [0.0](/filings/0001193125-25-280182.md) | [0.0 d](/filings/0001534969-26-000009.md) | [0.0](/filings/0001534969-26-000025.md) | [0.0](/filings/0001193125-26-346862.md) | [0.0](/filings/0001193125-25-280182.md) | [0.0 d](/filings/0001534969-26-000009.md) | [0.0](/filings/0001534969-26-000025.md) | [0.0](/filings/0001193125-26-346862.md) |
| Cost of revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-065667.md) | [0.0](/filings/0000950170-25-104007.md) | [0.0](/filings/0001193125-25-280182.md) | [0.0 d](/filings/0001534969-26-000009.md) | [0.0](/filings/0001534969-26-000025.md) | [0.0](/filings/0001193125-26-346862.md) | [0.0](/filings/0001193125-25-280182.md) | [0.0 d](/filings/0001534969-26-000009.md) | [0.0](/filings/0001534969-26-000025.md) | [0.1](/filings/0001193125-26-346862.md) |
| Research and development | $m | [3.5](/filings/0000950170-24-122312.md) | [3.9 d](/filings/0000950170-25-042017.md) | [3.7](/filings/0000950170-25-065667.md) | [4.4](/filings/0000950170-25-104007.md) | [3.5](/filings/0001193125-25-280182.md) | [3.1 d](/filings/0001534969-26-000009.md) | [3.3](/filings/0001534969-26-000025.md) | [3.3](/filings/0001193125-26-346862.md) | [3.3](/filings/0001193125-25-280182.md) | [3.2 d](/filings/0001534969-26-000009.md) | [3.0](/filings/0001534969-26-000025.md) | [3.5](/filings/0001193125-26-346862.md) |
| Operating income | $m | [(8.2)](/filings/0000950170-24-122312.md) | [(8.8) d](/filings/0000950170-25-042017.md) | [(9.1)](/filings/0000950170-25-065667.md) | [(9.3)](/filings/0000950170-25-104007.md) | [(8.9)](/filings/0001193125-25-280182.md) | [(9.4) d](/filings/0001534969-26-000009.md) | [(9.3)](/filings/0001534969-26-000025.md) | [(9.3)](/filings/0001193125-26-346862.md) | [(9.0)](/filings/0001193125-25-280182.md) | [(9.0) d](/filings/0001534969-26-000009.md) | [(9.4)](/filings/0001534969-26-000025.md) | [(10.0)](/filings/0001193125-26-346862.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-122312.md) | [0.0 d](/filings/0000950170-25-042017.md) | [0.0](/filings/0000950170-25-065667.md) | [0.0](/filings/0000950170-25-104007.md) | [0.0](/filings/0001193125-25-280182.md) | [0.0 d](/filings/0001534969-26-000009.md) | [0.0](/filings/0001534969-26-000025.md) | [0.0](/filings/0001193125-26-346862.md) | [0.0](/filings/0001193125-25-280182.md) | [0.0 d](/filings/0001534969-26-000009.md) | [0.0](/filings/0001534969-26-000025.md) | [0.0](/filings/0001193125-26-346862.md) |
| Net income | $m | [(7.2)](/filings/0000950170-24-122312.md) | [(7.9) d](/filings/0000950170-25-042017.md) | [(8.1)](/filings/0001193125-25-280182.md) | [(8.3)](/filings/0001193125-25-280182.md) | [(7.9)](/filings/0001193125-25-280182.md) | [(8.6) d](/filings/0001534969-26-000009.md) | [(8.2)](/filings/0001193125-26-346862.md) | [(8.0)](/filings/0001193125-26-346862.md) | [(7.8)](/filings/0001193125-25-280182.md) | [(7.9) d](/filings/0001534969-26-000009.md) | [(8.4)](/filings/0001193125-26-346862.md) | [(9.1)](/filings/0001193125-26-346862.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0000950170-24-122312.md) | not reported | [(0.25)](/filings/0000950170-25-065667.md) | [(0.25)](/filings/0000950170-25-104007.md) | [(0.24)](/filings/0001193125-25-280182.md) | not reported | [(0.20)](/filings/0001534969-26-000025.md) | [(0.16)](/filings/0001193125-26-346862.md) | [(0.16)](/filings/0001193125-25-280182.md) | not reported | [(0.17)](/filings/0001534969-26-000025.md) | [(0.18)](/filings/0001193125-26-346862.md) |
| Basic EPS | $ per share | [(0.23)](/filings/0000950170-24-122312.md) | not reported | [(0.25)](/filings/0000950170-25-065667.md) | [(0.25)](/filings/0000950170-25-104007.md) | [(0.24)](/filings/0001193125-25-280182.md) | not reported | [(0.20)](/filings/0001534969-26-000025.md) | [(0.16)](/filings/0001193125-26-346862.md) | [(0.16)](/filings/0001193125-25-280182.md) | not reported | [(0.17)](/filings/0001534969-26-000025.md) | [(0.18)](/filings/0001193125-26-346862.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.7](/filings/0001534969-23-000112.md) | [3.9](/filings/0000950170-25-042017.md) | [4.2](/filings/0001534969-24-000085.md) | [4.7](/filings/0001534969-24-000152.md) | [2.7](/filings/0000950170-24-122312.md) | [4.0](/filings/0001534969-26-000009.md) | [5.2](/filings/0000950170-25-065667.md) | [5.0](/filings/0000950170-25-104007.md) | [4.1](/filings/0001193125-25-280182.md) | [3.9](/filings/0001193125-26-346862.md) | [4.2](/filings/0001534969-26-000025.md) | [4.4](/filings/0001193125-26-346862.md) |
| Current assets | $m | [47.5](/filings/0001534969-23-000112.md) | [61.3](/filings/0000950170-25-042017.md) | [53.8](/filings/0001534969-24-000085.md) | [51.5](/filings/0001534969-24-000152.md) | [51.1](/filings/0000950170-24-122312.md) | [47.6](/filings/0001534969-26-000009.md) | [47.3](/filings/0000950170-25-065667.md) | [40.9](/filings/0000950170-25-104007.md) | [44.5](/filings/0001193125-25-280182.md) | [40.8](/filings/0001193125-26-346862.md) | [49.7](/filings/0001534969-26-000025.md) | [48.1](/filings/0001193125-26-346862.md) |
| Total assets | $m | [90.1](/filings/0001534969-23-000112.md) | [95.4](/filings/0000950170-25-042017.md) | [89.9](/filings/0001534969-24-000085.md) | [84.9](/filings/0001534969-24-000152.md) | [79.0](/filings/0000950170-24-122312.md) | [72.6](/filings/0001534969-26-000009.md) | [118](/filings/0000950170-25-065667.md) | [112](/filings/0000950170-25-104007.md) | [108](/filings/0001193125-25-280182.md) | [102](/filings/0001193125-26-346862.md) | [93.5](/filings/0001534969-26-000025.md) | [86.7](/filings/0001193125-26-346862.md) |
| Current liabilities | $m | [13.5](/filings/0001534969-23-000112.md) | [24.4](/filings/0000950170-25-042017.md) | [24.6](/filings/0001534969-24-000085.md) | [24.8](/filings/0001534969-24-000152.md) | [24.2](/filings/0000950170-24-122312.md) | [24.8](/filings/0001534969-26-000009.md) | [23.4](/filings/0000950170-25-065667.md) | [23.6](/filings/0000950170-25-104007.md) | [23.5](/filings/0001193125-25-280182.md) | [24.2](/filings/0001193125-26-346862.md) | [23.4](/filings/0001534969-26-000025.md) | [24.4](/filings/0001193125-26-346862.md) |
| Total liabilities | $m | [14.6](/filings/0001534969-23-000112.md) | [25.3](/filings/0000950170-25-042017.md) | [25.1](/filings/0001534969-24-000085.md) | [25.1](/filings/0001534969-24-000152.md) | [24.4](/filings/0000950170-24-122312.md) | [24.8](/filings/0001534969-26-000009.md) | [23.4](/filings/0000950170-25-065667.md) | [23.6](/filings/0000950170-25-104007.md) | [25.9](/filings/0001193125-25-280182.md) | [26.5](/filings/0001193125-26-346862.md) | [25.9](/filings/0001534969-26-000025.md) | [27.4](/filings/0001193125-26-346862.md) |
| Shareholders' equity | $m | [75.4](/filings/0000950170-24-122312.md) | [70.2](/filings/0001534969-26-000009.md) | [64.8](/filings/0001193125-25-280182.md) | [59.8](/filings/0001193125-25-280182.md) | [54.7](/filings/0001193125-25-280182.md) | [47.8](/filings/0001193125-26-346862.md) | [94.8](/filings/0001193125-26-346862.md) | [88.2](/filings/0001193125-26-346862.md) | [82.2](/filings/0001193125-25-280182.md) | [75.4](/filings/0001193125-26-346862.md) | [67.6](/filings/0001193125-26-346862.md) | [59.4](/filings/0001193125-26-346862.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(7,594) d](/filings/0000950170-24-122312.md) | [(6,765) d](/filings/0000950170-25-042017.md) | [4,994](/filings/0000950170-25-065667.md) | [(5,928) d](/filings/0000950170-25-104007.md) | [(6,995) d](/filings/0001193125-25-280182.md) | [(6,260) d](/filings/0001534969-26-000009.md) | [(7,553)](/filings/0001534969-26-000025.md) | [(5,473) d](/filings/0001193125-26-346862.md) | [(6,477) d](/filings/0001193125-25-280182.md) | [(6,120) d](/filings/0001534969-26-000009.md) | [(8,774)](/filings/0001534969-26-000025.md) | [(6,311) d](/filings/0001193125-26-346862.md) |
| Capital expenditure | $k | [26.0 d](/filings/0000950170-24-122312.md) | [16.0 d](/filings/0000950170-25-042017.md) | [15.0](/filings/0000950170-25-065667.md) | [7.0 d](/filings/0000950170-25-104007.md) | [26.0 d](/filings/0001193125-25-280182.md) | [8.0 d](/filings/0001534969-26-000009.md) | [3.0](/filings/0001534969-26-000025.md) | [281 d](/filings/0001193125-26-346862.md) | [112 d](/filings/0001193125-25-280182.md) | [330 d](/filings/0001534969-26-000009.md) | [8.0](/filings/0001534969-26-000025.md) | [16.0 d](/filings/0001193125-26-346862.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.0](/filings/0001534969-23-000112.md) | [31.0](/filings/0001534969-24-000085.md) | [31.1](/filings/0001534969-24-000152.md) | [31.3](/filings/0000950170-24-122312.md) | [32.2](/filings/0000950170-25-065667.md) | [32.9](/filings/0000950170-25-104007.md) | [33.5](/filings/0001193125-25-280182.md) | [42.0](/filings/0001534969-26-000025.md) | [49.1](/filings/0001193125-26-346862.md) | [49.5](/filings/0001193125-25-280182.md) | [50.3](/filings/0001534969-26-000025.md) | [50.5](/filings/0001193125-26-346862.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,293,831 at 2021-08-25, from the cover of the [10-Q filed 2021-08-30](/filings/0001104659-21-111035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.